|Description||OSI-420 (CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells.|
|B0084-286627||10 mg||$198||In stock|
|B0084-286627||50 mg||$598||In stock|
|Synonyms||OSI-420; CP-473420; Desmethyl Erlotinib.|
|Application||For research used only|
JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted...
AG 99, an EGF receptor tyrosine kinase inhibitor, has been found to show activities in diagnosis, prevention and treatment of cancer.
PKI 166 is a potent EGFR-kinase inhibitor (IC50 = 0.7 nM), with >3000-fold selectivity against a panel of serine/threonine kinases. PKI 166 potently inhibits th...
Selatinib is a Epidermal growth factor receptor(EGFR) and ERbB-2 receptor antagonist as an analog of the quinazoline lapatinib with potential antineoplastic act...
Naquotinib is an irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity wit...
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
NRC-2694 is a small molecule antagonist of epidermal growth factor receptor (EGFR) signalling pathways, for the treatment of solid tumors.
ZD-4190, a substituted 4-anilinoquinazoline, is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of e...
Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...
CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbourin...
HDS 029 is a potent inhibitor of the ErbB receptor family including EGFR, ErbB2 and ErbB4 (IC50 = 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2, respect...
PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). It inhibits the autophosphorylation of wild-type EGFR in A549 cells and ...
MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...
AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...
Methyl 2,5-dihydroxycinnamate, a stable analog of erbstatin, is a stable, potent inhibitor of EGFR kinase activity. It is described to be four-times more stable...
AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...
Lazertinib, also known as YH-25448 and GNS-1480, is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible 3rd gene...
Rociletinib is a third-generation irreversible kinase inhibitor of epidermal growth factor receptor (EGFR). Rociletinib was shown to inhibit the proliferation o...